We use cookies to improve your experience on our website. Read about how we use cookies and how you can control them by reviewing the Cookie section of our Privacy Policy. By continuing to use this website, you consent to our use of these cookies.

  • BMS Science Search BMS recruiting trials
  • Bolder Science Powered by ClinicalTrials.gov
    This website is intended for healthcare professionals
    This website is intended for healthcare professionals
  • Sign Up
  • Log In
  • Sign up for an account to save the trials you’re interested in following. You can use one account across both BMS Science and Bolder Science to track clinical trials worldwide.
Sign up for an account to save the trials you’re interested in following. You can use one account across both BMS Science and Bolder Science to track clinical trials worldwide.
 
  • Clinical Trials
  • Molecular Pathways
  • About BMS Science
Cancel
    Tyrosine Kinase 2 (TYK2)
    • Immunology
    • BTK
    • CTLA-4
    • IL-13
    • MK2
    • PAD
    • S1P-1R
    • TLR 7/8
    • TYK2

    TYK2

    Tyrosine kinase 2 (TYK2) mediates the signals triggered by certain cytokines.1

    • IL-12-induced TYK2 activation initiates recruitment and phosphorylation of STAT4 which activates transcription of a major effector molecule in systemic immune disorders.1,2
    • IL-23 signaling through TYK2 is critical in the expansion and survival of pathogenic TH17 cells as well as the induction of innate lymphoid cells in autoimmunity.1-3
    • Activation by type I IFNs signaling through TYK2 in the B cell impacts pathways important in autoimmunity such as B cell differentiation, antibody production, and immunoglobulin isotype class switching.4

    TYK2 mediates immune and inflammatory signaling pathways critical in the pathophysiology of
    immune-mediated diseases5-12

    TYK2 Mechanism of Pathway Video

    Back to trial details

    References

    1. Ishizaki M, Akimoto T, Muromoto R, et al. J Immunol. 2011;187:181-189.
    2. Paunovic V, Carroll HP, Vandenbroeck K, et al. Rheumatology. 2008;47:771-776.
    3. Geremia AG, Arancibia-Carcamo CV, Fleming MPP, et al. J Exp Med. 2011;208(6):1127-1133.
    4. Ronnblom L, Eloranta M-L, Alm GV. Arthritis Rheum. 2006;54(2):408-420.
    5. Min X et al. J Biol Chem . 2015;290:27261-27270.
    6. Gillooly K et al. Poster presentation at ACR/ARHP 2016. Abstract 11L.
    7. Miao W et al. Poster presentation at ACR/ARHP 2016. Abstract 1911.
    8. Jani M et al. Ann Rheum Dis. 2014;73:1750-1752.
    9. Smith JA, Colbert RA. Arthritis Rheumatol. 2014;66:231-241.
    10. Hofer MJ, Campbell IL. Cytokine Growth Factor Rev. 2013;24:257-267.
    11. Paniagua RT et al. J Am Acad Dermatol. 2011;65:389-403.
    12. O'Sullivan LA et al. Mol Immunol. 2007;44:2497-2506.
    13. Ghoreschi K et al. Immunol Rev. 2009;228:273-287.
    14. Tokarski JS et al. J Biol Chem. 2015;290:11061-11074.
    15. Simmons DP et al. J Immunol. 2012;188:3116-3126.
    16. Eloranta M-L, Rönnblom L. J Mol Med. 2016;94:1103-1110.
    Bristol Myers Squibb logo
    • Legal Notice
    • Privacy Policy
    • Contact Us
    • Sitemap
    IMM-US-2200386 05/22
    © 2022 BMS Science IMM-US-2200309 04/22
    BMS Science is a registered trademark of Bristol-Myers Squibb Company.

    You are now leaving www.BMSscience.com. BMS is not responsible for the content on third-party website

    Continue Cancel
    close-icon

    Log In

    Log in below to access your account on BMS Science or Bolder Science. If you have an existing Bolder Science account, please use your login credentials for that account here.

    Forgot Password

    Don't have an account? Sign Up

    close-icon

    Please enter your email address.

    You will receive a link to create a new password via email.

    Log In

    close-icon

    Create Account

    Use the form below to create one account that will be used across both BMS Science and Bolder Science. Clinical trials that you save on either site will be shown together on your dashboard on Bolder Science. If you already have an account, you can log in here.

    • 8 characters minimum
    • First character cannot be a number
    • Last character cannot be a number

    By clicking submit, you agree to the BMS Privacy Policy and Terms & Conditions

    close-icon

    Previous Next skip